BRPI0816498A2 - combinações potentes de zidovudina e drogas que selecionam para a mutuação k65r na polimerase do hiv - Google Patents
combinações potentes de zidovudina e drogas que selecionam para a mutuação k65r na polimerase do hivInfo
- Publication number
- BRPI0816498A2 BRPI0816498A2 BRPI0816498-3A BRPI0816498A BRPI0816498A2 BR PI0816498 A2 BRPI0816498 A2 BR PI0816498A2 BR PI0816498 A BRPI0816498 A BR PI0816498A BR PI0816498 A2 BRPI0816498 A2 BR PI0816498A2
- Authority
- BR
- Brazil
- Prior art keywords
- mutation
- combinations
- zidovudine
- select
- nucleoside
- Prior art date
Links
- 230000035772 mutation Effects 0.000 title abstract 5
- 229960002555 zidovudine Drugs 0.000 title abstract 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 230000003389 potentiating effect Effects 0.000 title abstract 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 abstract 6
- 239000002777 nucleoside Substances 0.000 abstract 5
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 abstract 3
- 229940124522 antiretrovirals Drugs 0.000 abstract 3
- 239000003903 antiretrovirus agent Substances 0.000 abstract 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 abstract 3
- 229940104230 thymidine Drugs 0.000 abstract 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 abstract 2
- 230000001934 delay Effects 0.000 abstract 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- 229930024421 Adenine Natural products 0.000 abstract 1
- 206010038997 Retroviral infections Diseases 0.000 abstract 1
- 229960004748 abacavir Drugs 0.000 abstract 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 abstract 1
- 229960000643 adenine Drugs 0.000 abstract 1
- 230000000798 anti-retroviral effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 229940104302 cytosine Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 abstract 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
combinações potentes de zidovudina e drogas que selecionam para a mutação k65r na polimerase do hiv. são fornecidas combinações de inibidores de transcriptase reversa de nucleotídeos antirretroviral, e seus métodos para a sua utilização no tratamento de infecções retrovirais. em uma modalidade, as combinações incluem agentes antirretrovirais de não-nucleosídeos de timidina, como o tenofovir-df, o abacavir, apd e dapd, que selecionam para a mutação k65r e doses relativamente baixas de zidovudina (azt) ou outros agentes antirretrovirais de nucleosídeos de timidina. os agentes antirretrovirais de nucleosídeos de timidina retardam o desenvolvimento da mutação k65r, e em doses baixas, têm menos probabilidade de produzir efeitos colaterais. em outra modalidade, as combinações incluem azt e dapd. o dapd retarda o desenvolvimento das tams, e o azt retarda o desenvolvimento da mutação k65r. em uma terceira modalidade, as combinações incluem adenina, citosina, timidina, e guanina nucleosídeos antivirais, ainda em combinação com pelo menos um agente antiviral adicional que funciona através de um mecanismo diferente de um nucleosídeo análogo. esta combinação tem o potencial de eliminar a presença do hiv em um paciente infectado.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99726407P | 2007-10-02 | 2007-10-02 | |
| US60/997,264 | 2007-10-02 | ||
| PCT/US2008/078207 WO2009045975A1 (en) | 2007-10-02 | 2008-09-29 | Potent combinations of zidovudine and drugs that select for the k65r mutation in the hiv polymerase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0816498A2 true BRPI0816498A2 (pt) | 2019-02-26 |
Family
ID=40526633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0816498-3A BRPI0816498A2 (pt) | 2007-10-02 | 2008-09-29 | combinações potentes de zidovudina e drogas que selecionam para a mutuação k65r na polimerase do hiv |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110053884A1 (pt) |
| EP (1) | EP2207553A4 (pt) |
| CN (1) | CN101878032A (pt) |
| BR (1) | BRPI0816498A2 (pt) |
| CA (1) | CA2701356A1 (pt) |
| MX (1) | MX2010003542A (pt) |
| RU (1) | RU2010117269A (pt) |
| WO (1) | WO2009045975A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011041512A2 (en) * | 2009-10-02 | 2011-04-07 | Emory University | Compositions and methods for treating mlv-infection, and preventing and treating mlv-initiated diseases |
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| US10821111B2 (en) | 2011-11-30 | 2020-11-03 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077279A (en) * | 1986-05-01 | 1991-12-31 | University Of Georgia Research Foundation, Inc. | 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition |
| US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
| GB9809213D0 (en) * | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| US6511983B1 (en) * | 1999-03-01 | 2003-01-28 | Biochem Pharma Inc. | Pharmaceutical combination of antiviral agents |
| WO2006001029A2 (en) * | 2004-06-25 | 2006-01-05 | Hetero Drugs Limited | Antiretroviral compositions |
-
2008
- 2008-09-29 US US12/680,874 patent/US20110053884A1/en not_active Abandoned
- 2008-09-29 MX MX2010003542A patent/MX2010003542A/es not_active Application Discontinuation
- 2008-09-29 WO PCT/US2008/078207 patent/WO2009045975A1/en not_active Ceased
- 2008-09-29 EP EP08836634A patent/EP2207553A4/en not_active Withdrawn
- 2008-09-29 BR BRPI0816498-3A patent/BRPI0816498A2/pt not_active IP Right Cessation
- 2008-09-29 RU RU2010117269/15A patent/RU2010117269A/ru not_active Application Discontinuation
- 2008-09-29 CA CA2701356A patent/CA2701356A1/en not_active Abandoned
- 2008-09-29 CN CN2008801181609A patent/CN101878032A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2701356A1 (en) | 2009-04-09 |
| WO2009045975A1 (en) | 2009-04-09 |
| EP2207553A4 (en) | 2010-12-29 |
| CN101878032A (zh) | 2010-11-03 |
| EP2207553A1 (en) | 2010-07-21 |
| MX2010003542A (es) | 2010-06-02 |
| US20110053884A1 (en) | 2011-03-03 |
| RU2010117269A (ru) | 2011-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35732A (es) | Composiciones terapéuticas de nucleótidos y nucleósidos y usos relacionados con las mismas | |
| Yegutkin | Adenosine metabolism in the vascular system | |
| BR112014013224A2 (pt) | inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais | |
| BRPI0515279A (pt) | preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados | |
| P. Burke et al. | Base-modified nucleosides as chemotherapeutic agents: past and future | |
| IL307486A (en) | Nucleoside and nucleotide analogs as antiviral agents | |
| De Jonghe et al. | An overview of marketed nucleoside and nucleotide analogs | |
| MX2015009006A (es) | Oligonucleotidos inhibitorios y su uso en terapia. | |
| BR9915636A (pt) | Método para promover secreções cervicais e vaginais | |
| Vittori et al. | N-Cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A1 adenosine receptor | |
| BRPI0717510B8 (pt) | análogos de oligonucleotídeo cpg contendo análogos t hidrofóbicos com atividade imunoestimulatória intensificada e composição farmacêutica que os compreende | |
| BRPI0513196A (pt) | formulações tópicas antivirais | |
| CL2013003053A1 (es) | Compuesto que comprende un oligonucleotido modificado que consiste en de 10 a 30 nucleósidos unidos y definidos por un grupo de secuencias específicas; composicion que comprende dicho compuesto; uso para tratar enfermedades relacionadas con el virus de la hepatitis b (vhb). | |
| NZ601486A (en) | 2',4'-substituted nucleosides as antiviral agents | |
| PE20051161A1 (es) | Metodos para tratar la infeccion por vih | |
| Cardoso et al. | Impact of ectonucleotidases in autonomic nervous functions | |
| BRPI0606324A2 (pt) | derivados de purina agindo como agonistas de receptor de a2a | |
| BRPI0816498A2 (pt) | combinações potentes de zidovudina e drogas que selecionam para a mutuação k65r na polimerase do hiv | |
| JP2005508297A5 (pt) | ||
| BR112022006476A2 (pt) | Oligonucleotídeos com análogos de nucleosídeos | |
| Jacobson et al. | Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets | |
| Rajapaksha et al. | A guide for the synthesis of key nucleoside scaffolds in drug discovery | |
| Sahu et al. | 4′‐Selenonucleosides as next‐generation nucleosides | |
| Valdés et al. | Adenosine: Synthetic methods of its derivatives and antitumor activity | |
| Moon et al. | Synthesis of 5′-substituted fluoro-neplanocin A analogues: importance of a hydrogen bonding donor at 5′-position for the inhibitory activity of S-adenosylhomocysteine hydrolase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2513 DE 06-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |